TNF Inhibitors and Uveitis in Ankylosing Spondylitis.
10.4078/jkra.2009.16.1.48
- Author:
Hee Sun KIM
1
;
Tae Jong KIM
;
Sang Cheol BAE
;
Dae Hyun YOO
;
Jae Bum JUN
;
Tae Hwan KIM
Author Information
1. Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Diseases, Hanyang University College of Medicine, Seoul, Korea. thkim@hanyang.ac.kr
- Publication Type:Case Report
- Keywords:
Ankylosing spondylitis;
TNF inhibitor;
Uveitis
- MeSH:
Antibodies, Monoclonal;
Humans;
Etanercept;
Infliximab;
Immunoglobulin G;
Receptors, Tumor Necrosis Factor;
Spondylitis, Ankylosing;
Uveitis
- From:The Journal of the Korean Rheumatism Association
2009;16(1):48-53
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Uveitis is the most common extra-articular manifestation of ankylosing spondylitis, and this occurs in 30~50% of the patients with ankylosing spondylitis. The main symptoms of ankylosing spondylitis are usually highly responsive to TNF inhibitors, but the effects of TNF inhibitors on uveitis are inconsistent. We report here on sixteen cases of new onset uveitis during etanercept therapy in patients with ankylosing spondylitis and they had no histories of uveitis. The symptoms of ankylosing spondyltiis, other than the uveitis, were well controlled during etanercept therapy. Six patients had histories of infliximab therapy before undergoing etanercept therapy, and uveitis did not develop during this infliximab therapy. Uveitis can develop during the course of ankylosing spondylitis, yet there is a possibility of a temporal relationship between etanercept therapy and uveitis.
